John R. Moore

CIK: 0001191702

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (42.1%)

Position reduction

Option Exercises (M)6 (31.6%)

Derivative conversions

Awards (A)5 (26.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EWTX

Edgewise Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (19 total)

EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
65K shares-
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Exercise(M)
Direct
6.7K shares-
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Sale(S)
Direct
2.4K shares at avg. $43.81$107K
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Sale(S)
Direct
59 shares at avg. $44.41$3K
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Sale(S)
Direct
99 shares at avg. $44.50$4K
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Sale(S)
Direct
2.4K shares at avg. $43.80$106K
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Exercise(M)
Direct
5.8K shares-
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Award(A)
Restricted Stock Units
Direct
32.5K shares-
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
65K shares-
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2025
Award(A)
Stock Option (Right to Buy)
Direct
161.3K shares-
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2025
Sale(S)
Direct
2.1K shares at avg. $13.39$28K
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2025
Award(A)
Restricted Stock Units
Direct
26.9K shares-
EWTX
Edgewise Therapeutics, Inc.
Aug 12, 2025
Exercise(M)
Direct
5.8K shares-
EWTX
Edgewise Therapeutics, Inc.
May 2, 2025
Sale(S)
Direct
1.9K shares at avg. $16.45$32K
EWTX
Edgewise Therapeutics, Inc.
May 1, 2025
Exercise(M)
Direct
5.2K shares-
EWTX
Edgewise Therapeutics, Inc.
Sep 23, 2024
Sale(S)
Direct
20.9K shares at avg. $27.63$578K
EWTX
Edgewise Therapeutics, Inc.
Sep 23, 2024
Exercise(M)
Direct
20.9K shares at avg. $0.71$15K
EWTX
Edgewise Therapeutics, Inc.
Sep 20, 2024
Sale(S)
Direct
50K shares at avg. $28.37$1.4M
EWTX
Edgewise Therapeutics, Inc.
Sep 20, 2024
Exercise(M)
Direct
50K shares at avg. $0.71$36K

		Type	Shares	Price		Ownership
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	65,000	-	-	Direct
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Exercise(M)	6,718	-	$0	Direct
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Sale(S)	2,439	$43.81	$106,848	Direct
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Sale(S)	59	$44.41	$2,620	Direct
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Sale(S)	99	$44.50	$4,406	Direct
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Sale(S)	2,419	$43.80	$105,949	Direct
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Exercise(M)	5,781	-	$0	Direct
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Award(A) Restricted Stock Units	32,500	-	-	Direct
Aug 12, 2026	EWTX Edgewise Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	65,000	-	-	Direct
Aug 12, 2025	EWTX Edgewise Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	161,250	-	-	Direct
Aug 12, 2025	EWTX Edgewise Therapeutics, Inc.	Sale(S)	2,098	$13.39	$28,097	Direct
Aug 12, 2025	EWTX Edgewise Therapeutics, Inc.	Award(A) Restricted Stock Units	26,875	-	-	Direct
Aug 12, 2025	EWTX Edgewise Therapeutics, Inc.	Exercise(M)	5,781	-	-	Direct
May 2, 2025	EWTX Edgewise Therapeutics, Inc.	Sale(S)	1,930	$16.45	$31,757	Direct
May 1, 2025	EWTX Edgewise Therapeutics, Inc.	Exercise(M)	5,209	-	-	Direct
Sep 23, 2024	EWTX Edgewise Therapeutics, Inc.	Sale(S)	20,922	$27.63	$578,064	Direct
Sep 23, 2024	EWTX Edgewise Therapeutics, Inc.	Exercise(M)	20,922	$0.71	$14,855	Direct
Sep 20, 2024	EWTX Edgewise Therapeutics, Inc.	Sale(S)	50,000	$28.37	$1,418,510	Direct
Sep 20, 2024	EWTX Edgewise Therapeutics, Inc.	Exercise(M)	50,000	$0.71	$35,500	Direct

1-19 of 19 transactions

About MOORE JOHN R

MOORE JOHN R (SEC CIK 0001191702) files insider reports with the SEC as General Counsel of Edgewise Therapeutics, Inc. (EWTX).

Signal8 holds 5 ownership filings by MOORE JOHN R, all Form 4s, filed between Sep 24, 2024 and Aug 17, 2026. Those filings report 19 transactions, from Sep 20, 2024 to Aug 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on MOORE JOHN R's filings is in BOULDER, CO.

Recent filings by MOORE JOHN R

Aug 12, 2026: Grant or award of EWTX derivative securities (Form 4, code A).
Aug 12, 2026: Option exercise of EWTX shares (Form 4, code M).
Aug 12, 2026: Open-market sales of EWTX shares (4 lines, Form 4, code S).
Aug 12, 2026: Option exercise of EWTX shares (Form 4, code M).
Aug 12, 2026: Grants or awards of EWTX derivative securities (2 lines, Form 4, code A).

Other insiders filing for Edgewise Therapeutics, Inc. (EWTX)

Fox Jonathan C, Director
Nofi Michael, Chief Financial Officer
Donovan Joanne M., CMO
Russell Alan J, Chief Scientific Officer
Derakhshan Behrad, Chief Business Officer
KOCH KEVIN, President and CEO

How to read Form 4 transaction codes